Pharmaceutical companies just raised list prices for over 500 medicines, including Novo Nordisk’s Ozempic, Gilead’s HIV-1 ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

And Gilead appears to be reaping the benefits ... Agencies sometimes choose not to list drugs because they cost more than existing treatments that perform equally well or because incremental ...

Livdelzi will launch at a list price of $12,606 for a 30-day treatment ... Seigerman predicted peak sales of $847 million for Gilead's drug. Both the PPAR drugs compete with Intercept Pharma's ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Technology is advancing at a rapid pace, transforming all areas of our lives and leaving barely any aspect of it unimpacted.  This is not a new phenomenon by any degree. Many centuries ago, the ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...